How Effective Is Lomustine for Glioblastoma Treatment?

Lomustine is one of a small number of chemotherapy drugs that reliably crosses the blood-brain barrier, which is why it has remained a mainstay in glioblastoma treatment for decades despite being developed in the 1960s. It is used both as a frontline agent in certain combination regimens and as a go-to option when glioblastoma comes back after initial treatment. Its effectiveness, though, hinges heavily on a molecular feature of the tumor itself, and the drug carries side effects and access issues that shape how oncologists use it in practice.

How Lomustine Works Against Glioblastoma

Lomustine (also called CCNU) belongs to a class of drugs known as nitrosoureas. It damages tumor DNA by attaching chemical groups to it, creating what are called alkyl adducts. The most therapeutically important of these are cross-links between the two strands of the DNA double helix. These interstrand cross-links are especially difficult for cells to repair, and when a rapidly dividing glioblastoma cell encounters them, it often triggers cell death. This mechanism is distinct from temozolomide, the other major alkylating drug used in glioblastoma, which primarily creates a different type of DNA damage that does not involve cross-linking the two strands together.

A key practical advantage of lomustine is that it dissolves in fat, which allows it to pass through the blood-brain barrier and reach tumor cells inside the brain. Once swallowed, the drug is rapidly converted in the liver and gut into active metabolites. The parent compound itself is essentially undetectable in the blood because it is so completely transformed during its first pass through the body. The two main active metabolites reach peak blood levels about two to four hours after a dose and have half-lives in the range of roughly three hours, though there is considerable person-to-person variability in how much active drug ultimately circulates.

The MGMT Question

Whether lomustine works well against a given glioblastoma depends largely on one molecular marker: MGMT promoter methylation. MGMT is a DNA repair enzyme that can undo exactly the kind of damage lomustine inflicts. When the gene encoding MGMT is silenced through a chemical process called methylation, the tumor loses much of its ability to fix the drug’s damage, making the cancer far more vulnerable to treatment.

This is not a subtle difference. A review of the evidence found that lomustine’s activity in recurrent glioblastoma is largely restricted to patients whose tumors carry MGMT promoter methylation, and that no other agent, with the possible exception of regorafenib, has shown superior activity to lomustine in that setting.¹ In practice, this means neuro-oncologists test every glioblastoma for MGMT status, and that result substantially influences whether lomustine-based regimens are recommended.

First-Line Use With Temozolomide

The standard first-line treatment for glioblastoma has long been surgery followed by radiation with concurrent temozolomide and then additional cycles of temozolomide alone. But for patients whose tumors are MGMT-methylated, adding lomustine to temozolomide may offer a meaningful survival advantage.

The key trial behind this approach, known as CeTeG/NOA-09, randomized patients with newly diagnosed MGMT-methylated glioblastoma to either standard temozolomide or the lomustine-temozolomide combination. Median overall survival was about 48 months in the combination group compared with roughly 31 months with temozolomide alone.² That is a striking difference in a disease where median survival with standard care is typically around 15 months. The trial was relatively small, and the statistical significance was borderline, so whether this combination should be standard of care for all MGMT-methylated patients remains debated. Still, many centers now offer it, and some guidelines list it as an option for this specific patient group.

An important companion analysis looked at whether the extra chemotherapy came at a cost to patients’ day-to-day functioning. It found no meaningful difference in health-related quality of life between the two treatment groups, and while there was a tiny statistical difference in a cognitive screening test favoring temozolomide alone, it amounted to less than two points on a 30-point scale over four years, a gap that is not considered clinically relevant.³ That finding matters because it suggests the survival benefit is not being purchased with a substantially worse experience during treatment.

Recurrent Glioblastoma and the Bevacizumab Story

When glioblastoma returns after initial treatment, options narrow considerably. Lomustine is one of the most commonly used drugs in this setting, often serving as the control arm in clinical trials testing newer agents. One of the most closely watched questions was whether adding bevacizumab, a drug that blocks blood vessel growth in tumors, would improve outcomes when combined with lomustine.

An earlier phase 2 trial, called BELOB, looked promising. At nine months, about 63% of patients receiving bevacizumab plus lomustine were still alive, compared with 43% receiving lomustine alone.⁴ These numbers generated genuine excitement in the field.

But the larger, definitive phase 3 trial told a different story. The EORTC 26101 trial enrolled over 400 patients and found that the combination did not extend overall survival. Median survival was about 9 months in the combination group and about 8.6 months with lomustine alone. Progression-free survival was longer with the combination (about 4.2 months versus 1.5 months), meaning tumors took longer to show signs of growing again on scans, but this did not translate into patients living longer.⁵ The combination also caused substantially more side effects: serious adverse events occurred in about 64% of patients receiving both drugs, compared with 38% on lomustine alone.⁶

The disconnect between progression-free survival and overall survival is worth understanding. Bevacizumab can reduce swelling and inflammation around tumors, which makes scans look better and can relieve symptoms temporarily, but these scan improvements do not always mean the tumor is actually being controlled long-term. This trial is now a cautionary example in neuro-oncology about relying too heavily on imaging as a proxy for real benefit.

Tumor Treating Fields and the Triple Combination

Tumor Treating Fields (TTFields) are a newer treatment modality that uses alternating electric fields delivered through adhesive arrays worn on the scalp to disrupt cell division. After a trial showed that TTFields added to temozolomide improved survival in newly diagnosed glioblastoma, researchers naturally asked whether combining TTFields with the lomustine-temozolomide regimen could push outcomes even further.

An early retrospective analysis of 16 patients treated with this triple combination found it was feasible and safe, with a median progression-free survival of 20 months and high patient adherence to the TTFields device (about 83% usage rate). Blood-related side effects of grade 3 or higher were seen in seven patients, and liver-related toxicity of that severity in four, which was in the expected range for the chemotherapy backbone.⁷ Lab work has offered a mechanistic rationale: in glioblastoma cell lines, TTFields given alongside lomustine or lomustine plus temozolomide showed additive effects in cells that express MGMT and synergistic effects in cells that do not.⁸ Larger prospective trials will be needed to confirm whether this three-part strategy genuinely extends life.

Side Effects and Tolerability

Lomustine’s main dose-limiting side effect is bone marrow suppression, particularly low platelet counts (thrombocytopenia) and low white blood cell counts (leukopenia). These effects are delayed compared with many other chemotherapy drugs, typically reaching their lowest point four to six weeks after a dose. Because of this lag, lomustine is usually given once every six weeks, with blood counts checked before each cycle to confirm adequate recovery.

In a study of 166 patients with progressive gliomas treated with lomustine, about 87% did not experience any toxicity above grade 3. Severe thrombocytopenia and leukopenia occurred in a small minority, and serious nausea or other severe side effects were uncommon.⁹ That said, the cumulative effect on bone marrow means that some patients eventually need dose reductions or treatment breaks, particularly those who have already received extensive prior chemotherapy or radiation.

Beyond blood counts, there are less common but real concerns. Nausea and vomiting can occur within hours of taking the capsules, though modern anti-nausea medications help considerably. Liver enzyme elevations happen occasionally and are usually monitored with routine blood work. Pulmonary toxicity, while rare, has been reported with prolonged use of nitrosoureas and is something oncologists watch for, especially in patients who have been on the drug for many cycles.

What Makes Tumors Resistant

Even in patients with MGMT-methylated tumors, lomustine does not work forever. Resistance eventually develops, and understanding why is an active area of research. MGMT itself is the best-understood resistance mechanism: tumors that initially lack MGMT expression can re-acquire it, or cells within a heterogeneous tumor that never lost MGMT can survive treatment and repopulate the cancer.

But there is more to resistance than MGMT. Because lomustine creates interstrand cross-links, the repair pathway that handles those specific lesions, called homologous recombination, becomes a potential escape route for the tumor. Research has shown that pharmacologically inhibiting key components of homologous recombination, such as the Rad51 protein, can significantly enhance lomustine’s killing effect on glioblastoma cells. In a mouse model, a Rad51 inhibitor combined with lomustine reduced tumor growth more effectively than either agent alone.¹⁰ These findings are still preclinical, but they point toward strategies that could eventually extend the usefulness of lomustine in the clinic.

A recent review noted that while resistance and response to temozolomide have been linked to both MGMT status and the mismatch repair pathway, our understanding of resistance mechanisms unique to nitrosoureas beyond MGMT remains limited.¹¹ This is a significant gap because tumors that develop resistance to temozolomide through mismatch repair deficiency often acquire a so-called hypermutation pattern that is associated with worse outcomes, a phenomenon that appears less common with lomustine.

How Lomustine Differs From Related Drugs

Temozolomide and carmustine (BCNU) are the two drugs most frequently compared with lomustine in glioblastoma. All three are alkylating agents, but they differ in meaningful ways.

Temozolomide creates a different primary type of DNA damage that does not include the interstrand cross-links characteristic of nitrosoureas. This distinction may explain why lomustine-containing regimens sometimes produce different outcomes than temozolomide alone, particularly in certain tumor subtypes. In IDH-mutant oligodendrogliomas, for instance, retrospective analyses suggest that the PCV regimen (which includes lomustine as its most active component) may be more effective than temozolomide, possibly because those highly treatment-sensitive tumors are especially vulnerable to the additional types of DNA damage lomustine inflicts.¹²

Another interesting difference involves drug efflux pumps. Tumor cells often try to push chemotherapy drugs out before they can do their work, using transporter proteins like ABCB1. Research using gene-editing techniques found that knocking out ABCB1 improved the response to temozolomide and carmustine but did not change the response to lomustine, suggesting lomustine is not a substrate for this particular efflux pump.¹³ That is a potential advantage: one common resistance mechanism simply does not apply to lomustine.

Carmustine, the other nitrosourea, breaks down into reactive intermediates faster than lomustine and is sometimes considered more potent. But carmustine is primarily used as biodegradable wafers placed directly into the surgical cavity or given intravenously, whereas lomustine is taken as a capsule at home. The oral route makes lomustine far more convenient for patients and is a major reason it remains the preferred nitrosourea for systemic glioblastoma treatment.

Use in Older Patients

Glioblastoma disproportionately affects older adults, and treatment decisions in patients over 70 require balancing potential benefit against the reality that aggressive chemotherapy is harder to tolerate with age. The CeTeG trial, which showed the survival benefit of lomustine-temozolomide, enrolled patients up to age 70 but not beyond, leaving a gap in evidence for the oldest patients.

A multicenter retrospective study specifically looked at 17 patients over age 70 (median age 72) treated with lomustine-temozolomide. Median progression-free survival was about 13.5 months and median overall survival was roughly 21 months, with a median of five chemotherapy courses completed.¹⁴ The authors described these results as encouraging and the regimen as feasible in this age group, though the study was small and retrospective. For many elderly patients, abbreviated radiation with temozolomide alone or even lomustine alone remains the more common approach, with the decision depending heavily on functional status and the patient’s own goals.

The Price Crisis

Lomustine’s clinical story cannot be separated from its economic one. In late 2017, the price of lomustine in the United States jumped by roughly 1,500%. For a drug that had been generic for decades and cost relatively little, the increase was jarring. A survey of neuro-oncology providers found that about 73% reported the price hike negatively affected their patients’ care, and 41% said patients were forced to switch to alternative therapies or skip treatment entirely because of cost and insurance denials.¹⁵

The situation highlighted a broader vulnerability in oncology: when a critical drug has only one manufacturer and no approved therapeutic substitutes, patients are exposed to supply and pricing shocks that can directly affect their survival. Lomustine, despite being an old and essential medication, had no price competition because the market was too small to attract generic manufacturers. For patients outside the United States, pricing varies substantially depending on national drug-pricing policies, but the American experience served as a wake-up call about pharmaceutical market dynamics in rare cancers.

Pseudoprogression After Lomustine-Based Treatment

One practical challenge with lomustine-based regimens is distinguishing true tumor growth from pseudoprogression on brain scans. Pseudoprogression refers to imaging changes that look like the tumor is getting worse but are actually caused by inflammation and treatment effects. This phenomenon is well known with temozolomide-radiation combinations, but it also occurs after lomustine-temozolomide chemoradiation and can appear late and persist for an unusually long time. Researchers have explored specialized PET scanning using an amino acid tracer called FET to help tell the two apart, since standard MRI can be ambiguous.¹⁶ Getting this distinction right is critical because misidentifying pseudoprogression as true progression could lead to prematurely stopping an effective treatment or unnecessarily switching to second-line therapy.

Experimental Delivery Systems

Although lomustine already crosses the blood-brain barrier on its own, researchers are experimenting with nanoparticle-based delivery systems designed to improve how much drug reaches tumor cells while reducing exposure to healthy tissue. One approach uses liposomes coated with a surfactant called polysorbate 80, which appears to enhance transport across brain blood vessels. In laboratory models, this formulation showed roughly 1.5-fold higher permeability across an artificial blood-brain barrier compared with uncoated liposomes and reduced glioma cell viability more effectively than the free drug without damaging the surrounding endothelial cells.¹⁷

Another line of work uses superparamagnetic iron oxide nanoparticles conjugated with folic acid to deliver lomustine preferentially to glioblastoma cells, which often overexpress folate receptors.¹⁸ Both of these approaches remain in the laboratory stage, and it will be years before any reach clinical trials. But they reflect a broader effort to modernize the delivery of an old drug whose fundamental anticancer activity is well established, rather than replacing it with something new.